NewEdge Advisors LLC Lowers Stock Holdings in Edwards Lifesciences Corporation $EW

Key Points

• NewEdge Advisors LLC significantly reduced its stake in Edwards Lifesciences by 68.5%, selling 71,678 shares and holding 32,972 shares worth approximately $2.39 million.
• Multiple analysts have raised their target prices for Edwards Lifesciences, with firms like Stifel Nicolaus and Barclays setting targets at $95.00 and recommending a "buy" or "overweight" rating.
• Insider selling has also been noted, with key executives offloading shares, indicating a possible decrease in confidence or liquidity, as the total insider sales in the last three months reached approximately $1.7 million.

NewEdge Advisors LLC reduced its stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 68.5% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 32,972 shares of the medical research company's stock after selling 71,678 shares during the period. NewEdge Advisors LLC's holdings in Edwards Lifesciences were worth $2,390,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of EW. Quantbot Technologies LP purchased a new position in shares of Edwards Lifesciences in the 1st quarter worth approximately $26,000. Vega Investment Solutions bought a new stake in Edwards Lifesciences during the 4th quarter valued at $27,000. SouthState Corp bought a new position in shares of Edwards Lifesciences in the first quarter worth $27,000. Global X Japan Co. Ltd. increased its holdings in shares of Edwards Lifesciences by 116.1% in the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after purchasing an additional 216 shares during the period. Finally, Tradewinds Capital Management LLC increased its holdings in shares of Edwards Lifesciences by 102.5% in the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock worth $29,000 after purchasing an additional 205 shares during the period. Hedge funds and other institutional investors own 79.46% of the company's stock.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares of the company's stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider directly owned 206,900 shares of the company's stock, valued at approximately $16,150,614. The trade was a 4.15% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,014 shares of company stock valued at $1,698,844. Insiders own 1.29% of the company's stock.

Edwards Lifesciences Stock Performance

NYSE:EW traded down $0.51 during trading hours on Friday, reaching $77.50. The company had a trading volume of 6,301,589 shares, compared to its average volume of 3,595,766. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52 week low of $64.00 and a 52 week high of $83.00. The firm has a market cap of $45.50 billion, a price-to-earnings ratio of 11.15, a PEG ratio of 3.76 and a beta of 1.07. The firm's 50 day moving average price is $78.92 and its 200-day moving average price is $75.39.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the previous year, the firm posted $0.70 EPS. The firm's revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analysts Set New Price Targets

EW has been the topic of a number of research analyst reports. Canaccord Genuity Group increased their target price on Edwards Lifesciences from $75.00 to $81.00 and gave the company a "hold" rating in a research note on Friday, July 25th. Stifel Nicolaus increased their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "buy" rating in a report on Friday, July 25th. JPMorgan Chase & Co. increased their target price on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock a "neutral" rating in a report on Friday, July 25th. Piper Sandler raised their price objective on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the stock an "overweight" rating in a report on Friday, July 25th. Finally, William Blair raised shares of Edwards Lifesciences to a "strong-buy" rating in a research note on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $86.26.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.